Citigroup Trims COMPASS Pathways (NASDAQ:CMPS) Target Price to $46.00

COMPASS Pathways (NASDAQ:CMPS – Get Rating) had its price objective decreased by Citigroup from $49.00 to $46.00 in a report published on Friday, The Fly reports. Citigroup currently has a buy rating on the stock.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $20.07 on Friday. The firm has a market cap of $853.18 million, a price-to-earnings ratio of -10.09 and a beta of 2.54. COMPASS Pathways has a 52 week low of $6.54 and a 52 week high of $49.51. The firm has a 50-day moving average price of $11.95 and a two-hundred day moving average price of $12.21.

COMPASS Pathways (NASDAQ:CMPS – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.18. During the same quarter in the previous year, the business posted ($0.35) earnings per share. As a group, sell-side analysts forecast that COMPASS Pathways will post -2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ghost Tree Capital LLC lifted its position in shares of COMPASS Pathways by 110.0% during the 4th quarter. Ghost Tree Capital LLC now owns 210,000 shares of the company’s stock valued at $4,641,000 after buying an additional 110,000 shares during the last quarter. PFS Investments Inc. lifted its holdings in COMPASS Pathways by 90.0% during the 4th quarter. PFS Investments Inc. now owns 30,812 shares of the company’s stock worth $681,000 after purchasing an additional 14,592 shares in the last quarter. Oasis Management Co Ltd. lifted its holdings in COMPASS Pathways by 31.7% during the 4th quarter. Oasis Management Co Ltd. now owns 207,911 shares of the company’s stock worth $4,595,000 after purchasing an additional 50,000 shares in the last quarter. Advanced Research Investment Solutions LLC bought a new position in COMPASS Pathways in the 4th quarter worth about $110,000. Finally, Virtus ETF Advisers LLC increased its stake in COMPASS Pathways by 27.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 6,913 shares of the company’s stock worth $153,000 after acquiring an additional 1,474 shares during the last quarter. Hedge funds and other institutional investors own 17.86% of the company’s stock.

COMPASS Pathways Company Profile

(Get Rating)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.